NZ598801A - Use of the sparc microenvironment signature in the treatment of cancer - Google Patents

Use of the sparc microenvironment signature in the treatment of cancer

Info

Publication number
NZ598801A
NZ598801A NZ598801A NZ59880110A NZ598801A NZ 598801 A NZ598801 A NZ 598801A NZ 598801 A NZ598801 A NZ 598801A NZ 59880110 A NZ59880110 A NZ 59880110A NZ 598801 A NZ598801 A NZ 598801A
Authority
NZ
New Zealand
Prior art keywords
tumor
sparc
antibody
immunostaining
histologic sections
Prior art date
Application number
NZ598801A
Inventor
Vuong Trieu
Neil Desai
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of NZ598801A publication Critical patent/NZ598801A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Abstract

Disclosed is a method for predicting the response of a tumor in a mammal to a chemotherapeutic regimen comprising: a. Preparing a plurality of histologic sections of the tumor to obtain a SPARC microenvironment signature (SMS); b. immunostaining one or more of the histologic sections of the tumor with a first antiSPARC antibody, wherein the first anti-SPARC antibody preferentially stains SPARC in tumor cells; c. immunostaining one or more of the histologic sections of the tumor with a second anti-SPARC antibody, wherein the second anti-SPARC antibody preferentially stains SPARC in fibroblasts; d. determining the staining of tumor cells, fibroblasts, inflammatory cells, acellular stroma/matrix, blood vessels, nerve tissue, and normal anatomy within the tumor, or any combinations thereof, with the first anti-SPARC antibody and the staining of tumor blood vessels and tumor stroma with the second antibody; e. predicting a positive response to the chemotherapeutic regimen if a predefined SMS is demonstrated by the immunostaining.
NZ598801A 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer NZ598801A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27696909P 2009-09-18 2009-09-18
PCT/US2010/049545 WO2011035274A1 (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Publications (1)

Publication Number Publication Date
NZ598801A true NZ598801A (en) 2014-07-25

Family

ID=43759058

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ598801A NZ598801A (en) 2009-09-18 2010-09-20 Use of the sparc microenvironment signature in the treatment of cancer

Country Status (13)

Country Link
US (1) US20120245089A1 (en)
EP (1) EP2478362B1 (en)
JP (1) JP2013505268A (en)
KR (1) KR20120092597A (en)
CN (1) CN102576016A (en)
AU (1) AU2010295324B2 (en)
BR (1) BR112012008316A2 (en)
CA (1) CA2774550A1 (en)
IL (1) IL218642A0 (en)
MX (1) MX2012003287A (en)
NZ (1) NZ598801A (en)
WO (1) WO2011035274A1 (en)
ZA (1) ZA201202657B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853810C (en) * 2009-05-28 2017-04-25 Vuong Trieu Use of 2 anti-sparc antibodies to predict response to chemotherapy
JP2013530166A (en) 2010-06-03 2013-07-25 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー Use of SPARC microenvironment signatures in cancer treatment
US11017533B2 (en) * 2016-11-10 2021-05-25 Hoffmann-La Roche Inc. Distance-based tumor classification

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5003621A (en) 1989-11-02 1991-03-26 Motorola, Inc. Direct conversion FM receiver
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US20070054271A1 (en) * 2003-03-20 2007-03-08 Dana-Farber Cancer Institute, Inc. Gene expression in breast cancer
ES2481672T3 (en) * 2003-07-17 2014-07-31 Pacific Edge Limited Markers for gastric cancer detection
CN102989009B (en) * 2003-12-31 2015-06-03 宾夕法尼亚州研究基金会 Methods for predicting and overcoming resistance to chemotherapy in ovarian cancer and for predicting colon cancer occurrence
AU2006249235B2 (en) * 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
GB0417740D0 (en) * 2004-08-10 2004-09-08 Uc3 Methods and kit for the prognosis of breast cancer
EP1813943B1 (en) * 2004-10-19 2009-09-23 Kumamoto University Novel diagnostic kit for malignant melanoma
AU2006237613A1 (en) * 2005-02-18 2006-10-26 Abraxis Bioscience, Inc. Q3 SPARC deletion mutant and uses thereof
EP2301531B1 (en) * 2005-02-18 2018-06-06 Abraxis BioScience, LLC Combinations and modes of administration of therapeutic agents and combination therapy
MX2008015939A (en) * 2006-06-16 2009-02-11 Univ Kumamoto Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same.
LT2117520T (en) * 2006-12-14 2018-12-10 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
US20100286058A1 (en) * 2007-03-09 2010-11-11 Isabella Tai Assessing Chemotherapy Resistance of Colorectal Tumors by Determining Sparc Hypermethylation
ES2389828T3 (en) * 2007-04-13 2012-11-02 Abraxis Bioscience, Inc. Compositions comprising SPARC polypeptides
US8927019B2 (en) * 2007-06-01 2015-01-06 Abraxis Bioscience, Llc Methods and compositions for treating recurrent cancer

Also Published As

Publication number Publication date
EP2478362B1 (en) 2016-05-11
JP2013505268A (en) 2013-02-14
CA2774550A1 (en) 2011-03-24
US20120245089A1 (en) 2012-09-27
ZA201202657B (en) 2013-09-25
AU2010295324B2 (en) 2015-04-30
IL218642A0 (en) 2012-05-31
BR112012008316A2 (en) 2017-06-06
WO2011035274A1 (en) 2011-03-24
EP2478362A1 (en) 2012-07-25
MX2012003287A (en) 2012-08-03
AU2010295324A1 (en) 2012-04-05
KR20120092597A (en) 2012-08-21
EP2478362A4 (en) 2013-09-11
CN102576016A (en) 2012-07-11

Similar Documents

Publication Publication Date Title
Martinez-Outschoorn et al. Cancer cells metabolically" fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors
Ruscetti et al. Tracking and functional characterization of epithelial–mesenchymal transition and mesenchymal tumor cells during prostate cancer metastasis
Martinez-Outschoorn et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment
AR084723A1 (en) microRNA (miRNA) AS A BIOMARCATOR FOR THE IDENTIFICATION OF FAMILY AND NON-FAMILY COLORRECTAL CANCER
AR080505A1 (en) METHODS FOR THE TREATMENT OF NON-HODKIN LYMPHOMA USING LENALIDOMIDE, AND GENETIC AND PROTEIC BIMARKERS AS INDICATORS
WO2011112903A3 (en) Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients
WO2013033396A3 (en) Fap-activated proteasome inhibitors for treating solid tumors
AR077901A1 (en) ANTI-C-MET ANTIBODY AND ITS USE FOR CANCER DETECTION AND DIAGNOSIS
GB2467467C (en) TAZ/WWTR1 for diagnosis and treatment of cancer
CL2007000876A1 (en) USE OF AN ANTAGONIST OF THE VASCULAR ENDOTELIAL GROWTH FACTOR (VEGF) IN COMBINATION WITH A SECOND AGENT UNDERSTANDING A MIELOID CELL REDUCING AGENT TO TREAT A RESISTANT TUMOR IN A SUBJECT; AND TUMOR DIAGNOSIS METHOD.
WO2012054747A3 (en) Methods and compositions for treating tumors using myeloid derived suppressor cells
WO2013124815A3 (en) Mesenchymal stem cells for in vitro modeling and cell-based therapy of human diseases and banks thereof
Albury et al. Constitutively active Akt1 cooperates with KRasG12D to accelerate in vivo pancreatic tumor onset and progression
WO2012154567A3 (en) Human invasion signature for prognosis of metastatic risk
PH12014502548A1 (en) Method for identifying ligands of the ahr receptor having therapeutic sebosuppressive activity, and said ligands
Balvan et al. Oxidative stress resistance in metastatic prostate cancer: Renewal by self-eating
WO2010033597A3 (en) Methods for detecting overexpression of sparc and therapeutic and diagnostic methods relating to same
Duan et al. The long noncoding RNA ZFAS1 potentiates the development of hepatocellular carcinoma via the microRNA-624/MDK/ERK/JNK/P38 signaling pathway
AR087363A1 (en) USE OF ANTIBODY I-3859 FOR THE DETECTION AND DIAGNOSIS OF CANCERES
NZ598801A (en) Use of the sparc microenvironment signature in the treatment of cancer
WO2012079088A3 (en) Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
WO2012151390A3 (en) A therapeutic and diagnostic target gene in acute myeloid leukemia
EP2589665A4 (en) Method for predicting therapeutic effect of immunotherapy on cancer patient, and gene set and kit to be used in the method
ES2509567T3 (en) Identification of genetic variation in affected tissues
MX2015013172A (en) Methods for determining prognosis of colorectal cancer.

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 20 SEP 2017 BY COMPUTER PACKAGES INC

Effective date: 20141118

LAPS Patent lapsed